142 related articles for article (PubMed ID: 22884145)
1. Overexpression of catalytic subunit M2 in patients with ovarian cancer.
Wang LM; Lu FF; Zhang SY; Yao RY; Xing XM; Wei ZM
Chin Med J (Engl); 2012 Jun; 125(12):2151-6. PubMed ID: 22884145
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers.
Huang Y; Liu X; Wang YH; Yeh SD; Chen CL; Nelson RA; Chu P; Wilson T; Yen Y
Urol Oncol; 2014 Jan; 32(1):51.e9-19. PubMed ID: 24360663
[TBL] [Abstract][Full Text] [Related]
3. The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms.
Wang P; Wu X; Chen W; Liu J; Wang X
Gynecol Oncol; 2007 Mar; 104(3):714-20. PubMed ID: 17204312
[TBL] [Abstract][Full Text] [Related]
4. Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro.
Morikawa T; Hino R; Uozaki H; Maeda D; Ushiku T; Shinozaki A; Sakatani T; Fukayama M
Hum Pathol; 2010 Dec; 41(12):1742-8. PubMed ID: 20825972
[TBL] [Abstract][Full Text] [Related]
5. Ribonucleotide reductase M2 subunit expression and prognostic value in nasopharyngeal carcinoma.
Han P; Lin ZR; Xu LH; Zhong Q; Zhu XF; Liang FY; Cai Q; Huang XM; Zeng MS
Mol Med Rep; 2015 Jul; 12(1):401-9. PubMed ID: 25695839
[TBL] [Abstract][Full Text] [Related]
6. E2F1 promote the aggressiveness of human colorectal cancer by activating the ribonucleotide reductase small subunit M2.
Fang Z; Gong C; Liu H; Zhang X; Mei L; Song M; Qiu L; Luo S; Zhu Z; Zhang R; Gu H; Chen X
Biochem Biophys Res Commun; 2015 Aug; 464(2):407-15. PubMed ID: 26093293
[TBL] [Abstract][Full Text] [Related]
7. Identification of ribonucleotide reductase M2 as a potential target for pro-senescence therapy in epithelial ovarian cancer.
Aird KM; Li H; Xin F; Konstantinopoulos PA; Zhang R
Cell Cycle; 2014; 13(2):199-207. PubMed ID: 24200970
[TBL] [Abstract][Full Text] [Related]
8. Klotho expression in epithelial ovarian cancer and its association with insulin-like growth factors and disease progression.
Lu L; Katsaros D; Wiley A; de la Longrais IA; Puopolo M; Yu H
Cancer Invest; 2008 Mar; 26(2):185-92. PubMed ID: 18259951
[TBL] [Abstract][Full Text] [Related]
9. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R
Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients.
Chen YJ; Yuan CC; Chow KC; Wang PH; Lai CR; Yen MS; Wang LS
Gynecol Oncol; 2005 Apr; 97(1):110-7. PubMed ID: 15790446
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of mammaglobin B in epithelial ovarian carcinomas.
Tassi RA; Bignotti E; Rossi E; Falchetti M; Donzelli C; Calza S; Ravaggi A; Bandiera E; Pecorelli S; Santin AD
Gynecol Oncol; 2007 Jun; 105(3):578-85. PubMed ID: 17343903
[TBL] [Abstract][Full Text] [Related]
12. Small interfering RNA (siRNA)-mediated silencing of the M2 subunit of ribonucleotide reductase: a novel therapeutic strategy in ovarian cancer.
Zhang M; Wang J; Yao R; Wang L
Int J Gynecol Cancer; 2013 May; 23(4):659-66. PubMed ID: 23466567
[TBL] [Abstract][Full Text] [Related]
13. High expression of ribonucleotide reductase subunit M2 correlates with poor prognosis of hepatocellular carcinoma.
Lee B; Ha SY; Song DH; Lee HW; Cho SY; Park CK
Gut Liver; 2014 Nov; 8(6):662-8. PubMed ID: 25368754
[TBL] [Abstract][Full Text] [Related]
14. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
15. Ribonucleotide reductase M2 subunit is a novel diagnostic marker and a potential therapeutic target in bladder cancer.
Morikawa T; Maeda D; Kume H; Homma Y; Fukayama M
Histopathology; 2010 Dec; 57(6):885-92. PubMed ID: 21166702
[TBL] [Abstract][Full Text] [Related]
16. Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker.
Yousef GM; Kyriakopoulou LG; Scorilas A; Fracchioli S; Ghiringhello B; Zarghooni M; Chang A; Diamandis M; Giardina G; Hartwick WJ; Richiardi G; Massobrio M; Diamandis EP; Katsaros D
Cancer Res; 2001 Nov; 61(21):7811-8. PubMed ID: 11691797
[TBL] [Abstract][Full Text] [Related]
17. [Relationship between raf kinase inhibitor protein and metastasis of ovarian carcinoma].
Wang Y; Yang J; Gao Y; Zhao XL; Li HZ; Yao Z
Zhonghua Fu Chan Ke Za Zhi; 2009 Jul; 44(7):522-8. PubMed ID: 19957553
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
19. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.
Shigemasa K; Tian X; Gu L; Tanimoto H; Underwood LJ; O'Brien TJ; Ohama K
Oncol Rep; 2004 Jun; 11(6):1153-9. PubMed ID: 15138549
[TBL] [Abstract][Full Text] [Related]
20. Methylation status and expression of human telomerase reverse transcriptase in ovarian and cervical cancer.
Widschwendter A; Müller HM; Hubalek MM; Wiedemair A; Fiegl H; Goebel G; Mueller-Holzner E; Marth C; Widschwendter M
Gynecol Oncol; 2004 May; 93(2):407-16. PubMed ID: 15099954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
